Organo-Post-Transition Metal Compounds
Medchemexpress LLC UCL 1684 dibromide | 199934-16-2 | 98.1% | 654.44 | 25 MG
UCL 1684 (dibromide) is a first nanomolar, non-peptidic small conductance calcium-activated potassium (SK) channel blocker. It is effective in preventing the development of atrial fibrillation due to potent atrial-selective inhibition of INa, causing atrial-selective prolongation of ERP secondary to induction of postrepolarization refractoriness. In vitro studies show it produces direct atrial-selective inhibition of sodium channel current (INa) and shifts SS inactivation of cardiac sodium channels. It also induces PRR, decreases Vmax, increases DTE, and extends the shortest S1-S1 interval.
- First nanomolar, non-peptidic SK channel blocker.
- Effective in preventing atrial fibrillation by atrial-selective inhibition of INa.
- Induces atrial-selective prolongation of ERP.
- Increases wenckebach cycle length in vivo.
Apexbio Technology LLC Benzoquinonium dibromide 311-09-1 50mg
Benzoquinonium dibromide is a small-molecule antagonist targeting nicotinic acetylcholine receptors (nAChRs) It is designed to inhibit neuronal acetylcholine receptor channel activity thereby regulating cholinergic neurotransmission Benzoquinonium dibromide exerts its biological activity primarily through blockade of nAChRs affecting the permeability of Na and K ions across neuronal membranes In in vitro studies using cultured fetal rat hippocampal neurons Benzoquinonium dibromide demonstrates dual effects at concentrations of 0 1 10 M it activates ion channel currents at conductance states of approximately 43 pS and 30 pS while also exhibiting channel-blocking activity at the open-channel state Based on these pharmacological properties Benzoquinonium dibromide holds research potential in neuropharmacology and neurophysiology for investigating cholinergic signaling pathways receptor activation mechanisms and receptor-channel interactions
Apexbio Technology LLC Benzoquinonium dibromide 311-09-1 10mg
Benzoquinonium dibromide is a small-molecule antagonist targeting nicotinic acetylcholine receptors (nAChRs) It is designed to inhibit neuronal acetylcholine receptor channel activity thereby regulating cholinergic neurotransmission Benzoquinonium dibromide exerts its biological activity primarily through blockade of nAChRs affecting the permeability of Na and K ions across neuronal membranes In in vitro studies using cultured fetal rat hippocampal neurons Benzoquinonium dibromide demonstrates dual effects at concentrations of 0 1 10 M it activates ion channel currents at conductance states of approximately 43 pS and 30 pS while also exhibiting channel-blocking activity at the open-channel state Based on these pharmacological properties Benzoquinonium dibromide holds research potential in neuropharmacology and neurophysiology for investigating cholinergic signaling pathways receptor activation mechanisms and receptor-channel interactions